Sanofi and AstraZeneca PLC’s Beyfortus (nirsevimab) has been approved by the European Commission for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV seasons, marking the first ever approval of an RSV prophylactic in a broad infant population, an the start of a new era in treatments for the infection.
AstraZeneca’s vaccines and immune therapies unit head Iskra Reic said the green light marked “a significant achievement for the scientific community and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?